Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Purpose: We have analyzed the outcome of mycosis fungoides (MF) and Sézary syndrome (SS) patients using the recent International Society for Cutaneous Lymphomas (ISCL)/European Organisation for Research and Treatment of Cancer (EORTC) revised staging proposal. Patients and Methods: Overall survival (OS), disease-specific survival (DSS), and risk of disease progression (RDP) were calculated for a cohort of 1,502 patients using univariate and multivariate models. Results: The mean age at diagnosis was 54 years, and 71% of patients presented with early-stage disease. Disease progression occurred in 34%, and 26% of patients died due to MF/SS. A significant difference in survival and progression was noted for patients with early-stage disease having patches alone (T1a/T2a) compared with those having patches and plaques (T1b/T2b). Univariate analysis established that (1) advanced skin and overall clinical stage, increased age, male sex, increased lactate dehydrogenase (LDH), and large-cell transformation were associated with reduced survival and increased RDP; (2) hypopigmented MF, MF with lymphomatoid papulosis, and poikilodermatous MF were associated with improved survival and reduced RDP; and (3) folliculotropic MF was associated with an increased RDP. Multivariate analysis established that (1) advanced skin (T) stage, the presence in peripheral blood of the tumor clone without Sézary cells (B0b), increased LDH, and folliculotropic MF were independent predictors of poor survival and increased RDP; (2) large-cell transformation and tumor distribution were independent predictors of increased RDP only; and (3) N, M, and B stages; age; male sex; and poikilodermatous MF were only significant for survival. Conclusion: This study has validated the recently proposed ISCL/EORTC staging system and identified new prognostic factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
WHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
A Prognostic Score for Advanced Hodgkin's Disease
Hasenclever, D., Diehl, V., Armitage, J. O., Assouline, D., Björkholm, M., Brusamolino, E., Canellos, G. P., Carde, P., Crowther, D., Cunningham, D., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392104 · Cited by 1,736
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citationFollicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
Thiers, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70989-4 · Cited by 974
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
Bradford, P. T., Devesa, S. S., Anderson, W. F., & Toro, J. R. (2009) · Blood · doi:10.1182/blood-2008-10-184168 · Cited by 709
Regulation of the Immune System by Sex Steroids*
GROSSMAN, C. J. (1984) · Endocrine Reviews · doi:10.1210/edrv-5-3-435 · Cited by 667
Cited by
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019) · Blood · doi:10.1182/blood-2018-11-881268 · Cited by 1,412
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 669
Self-citationPrince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Self-citationTrautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Self-citationScarisbrick, J. J., Prince, H. M., Vermeer, M. H., Quaglino, P., Horwitz, S., Porcu, P., Stadler, R., Wood, G. S., Beylot-Barry, M., Pham-Ledard, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.7142 · Cited by 430
Self-citationPrimary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.07.049 · Cited by 381
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome
da Silva Almeida, A. C., Abate, F., Khiabanian, H., Martinez-Escala, E., Guitart, J., Tensen, C. P., Vermeer, M. H., Rabadan, R., Ferrando, A., & Palomero, T. (2015) · Nature Genetics · doi:10.1038/ng.3442 · Cited by 379
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Jawed, S. I., Myskowski, P. L., Horwitz, S., Moskowitz, A., & Querfeld, C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.08.033 · Cited by 347
Wang, L., Ni, X., Covington, K. R., Yang, B. Y., Shiu, J., Zhang, X., Xi, L., Meng, Q., Langridge, T., Drummond, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3444 · Cited by 323
Willemze, R., Hodak, E., Zinzani, P. L., Specht, L., & Ladetto, M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt242 · Cited by 296
Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009
Talpur, R., Singh, L., Daulat, S., Liu, P., Seyfer, S., Trynosky, T., Wei, W., & Duvic, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0604 · Cited by 289
Willemze, R., Hodak, E., Zinzani, P. L., Specht, L., & Ladetto, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy133 · Cited by 281
Scarisbrick, J. J., Quaglino, P., Prince, H. M., Papadavid, E., Hodak, E., Bagot, M., Servitje, O., Berti, E., Ortiz‐Romero, P., Stadler, R., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17258 · Cited by 244
Self-citationPLCG1 mutations in cutaneous T-cell lymphomas
Vaqué, J. P., Gómez-López, G., Monsálvez, V., Varela, I., Martínez, N., Pérez, C., Domínguez, O., Graña, O., Rodríguez-Peralto, J. L., Rodríguez-Pinilla, S. M., et al. (2014) · Blood · doi:10.1182/blood-2013-05-504308 · Cited by 229
Specht, L., Dabaja, B., Illidge, T., Wilson, L. D., & Hoppe, R. T. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.008 · Cited by 227
Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases
Benner, M. F., Jansen, P. M., Vermeer, M. H., & Willemze, R. (2012) · Blood · doi:10.1182/blood-2011-08-376319 · Cited by 215
Kiel, M. J., Sahasrabuddhe, A. A., Rolland, D. C. M., Velusamy, T., Chung, F., Schaller, M., Bailey, N. G., Betz, B. L., Miranda, R. N., Porcu, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9470 · Cited by 209
Mycosis fungoides: A great imitator
Hodak, E., & Amitay-Laish, I. (2019) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2019.01.004 · Cited by 163
Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014) · Blood · doi:10.1182/blood-2013-09-525915 · Cited by 93
“Patients with advanced-stageMF/SS frequently relapse and often develop disease refractory to treatment with an unfavorable prognosis.(4) Overall survival (OS) has not been shown to benefit from aggressive intervention with cytotoxic agents.”
BackgroundReal-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
Hodak, E., Geskin, L., Guenova, E., Ortiz-Romero, P. L., Willemze, R., Zheng, J., Cowan, R., Foss, F., Mangas, C., & Querfeld, C. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00732-w · Cited by 47
“of body surface area [BSA], while T2 is characterized by these clinical features affecting ≥ 10% of BSA), patients with just patches tend to have a better prognosis than those with plaques [9].”
BackgroundPhotopheresis in the treatment of cutaneous T-cell lymphoma: current status
Zic, J. A. (2012) · Current Opinion in Oncology · doi:10.1097/01.cco.0000410158.56500.c4 · Cited by 25
“(ISCL)/EORTC revised-staging system [15].”
Beatty, P., Molloy, K., Porkert, S., Foley, M. P., Tobin, A., Trautinger, F., Scarisbrick, J., & Jonak, C. (2025) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15799 · Cited by 3
“10,11 MF is currently regarded as incurable and treatment options are aimed at controlling symptoms and induction and maintenance of remission.”
InfluentialSelf-citation
Metadata
- Authors
- Agar, N. S., Wedgeworth, E., Crichton, S., Mitchell, T. J., Cox, M., Ferreira, S., Robson, A., Calonje, E., Stefanato, C. M., Wain, E. M., Wilkins, B., Fields, P. A., Dean, A., Webb, K., Scarisbrick, J., Morris, S., & Whittaker, S. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-11-01
- Volume
- 28
- Issue
- 31
- Pages
- 4730-4739
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2147937827
- Cited by
- 853
- References
- 29
- FWCI
- 37.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.